BridgeBio shares fall 3.9% despite landmark trial results for rare muscle disorder
BBP-418 demonstrates consistent efficacy in Phase 3 FORTIFY study, positioning company for first FDA-approved LGMD therapy
BridgeBio Pharma shares declined 3.9% on Tuesday, closing at $71.39, even as the company released data from its Phase 3 FORTIFY trial showing that BBP-418 could become the first approved treatment for a rare and debilitating muscle disorder. The market reaction represents a potential mispricing, analysts say, given the strength of the clinical data and the company's position in an untapped therapeutic area.
The interim analysis from the FORTIFY trial demonstrated that BBP-418 produced rapid and sustained reductions in serum creatine kinase—a key biomarker of muscle damage—with improvements observed as early as three months and maintained through 12 months. Among patients treated for a full year, 59.6% achieved CK levels within twice the upper limit of normal, while 38.3% saw their levels normalize entirely, according to BridgeBio's investor presentation.
The functional outcomes were equally compelling. On the 100-meter timed test, a measure of ambulation critical to patients' daily independence, individuals receiving BBP-418 completed the distance approximately 31 seconds faster than those on placebo at the 12-month mark. On the 10-meter walk test, BBP-418-treated participants improved their speed by 0.13 meters per second from baseline, while the placebo group experienced a decline of 0.10 meters per second.
"Early separation from placebo on the 100-meter timed test suggests rapid onset of action and improvements in ambulation," the company stated in its release. The treatment effect was consistent across all predefined subgroups, including genotype, age, and baseline lung function.
Safety data showed BBP-418 was generally well-tolerated, with a profile comparable to placebo. Treatment-emergent adverse events occurred in 93.2% of BBP-418 patients versus 100% of placebo recipients, with serious adverse events reported in 5.4% of the treatment group compared to 7.9% of those receiving placebo. No treatment-related serious adverse events or deaths occurred during the study.
BridgeBio now plans to submit a New Drug Application to the FDA for traditional approval in the first half of 2026, with a potential U.S. launch in late 2026 or early 2027 if approved. The company is also engaging with European regulators to identify an expedited approval pathway. If successful, BBP-418 would mark the first therapy specifically approved for LGMD2I/R9 and potentially the first for any form of limb-girdle muscular dystrophy—a group of rare genetic disorders affecting approximately 5 to 10 per million people worldwide.
The significance of developing a treatment for LGMD2I/R9 cannot be overstated. The disease is relentlessly progressive, typically beginning in childhood or adolescence and leading to irreversible loss of motor function. Reduced life expectancy and quality-adjusted life years are primarily driven by cardiomyopathy—the weakening of the heart muscle—and loss of ambulation. Patients currently have no disease-modifying treatment options.
"If approved, BBP-418 could be the first approved therapy for individuals with LGMD2I/R9, and potentially the first approval of a therapy for any form of LGMD," BridgeBio noted in its announcement. The company's market capitalization stands at $14.4 billion, with analyst consensus price targets averaging $99.96, according to market data. Of the 21 analysts covering the stock, 20 rate it a buy or strong buy, with just one hold rating and no sell recommendations.
The disconnect between the clinical trial success and Tuesday's stock decline highlights what some analysts view as an opportunity. BridgeBio's shares have gained 129.8% over the past year, and the company's portfolio extends beyond BBP-418 to include programs for other genetic diseases. The biotechnology firm, headquartered in Palo Alto, California, reported revenue of $502 million over the trailing twelve months, representing 25.2% year-over-year growth.
As BridgeBio advances toward regulatory submission, investors will be watching closely for details on manufacturing scale-up, pricing strategy, and commercialization plans for a therapy that would enter a market with no existing competitors. The company's ability to execute on these fronts will determine whether BBP-418 can fulfill its potential as both a medical breakthrough and a commercial success.